Compare ICL & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICL | LNTH |
|---|---|---|
| Founded | 1968 | 1956 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.6B |
| IPO Year | 2001 | 2014 |
| Metric | ICL | LNTH |
|---|---|---|
| Price | $5.38 | $100.67 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.10 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 1.2M | 962.6K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.91 |
| Revenue | N/A | ★ $343,374,000.00 |
| Revenue This Year | $6.04 | N/A |
| Revenue Next Year | $3.27 | $14.19 |
| P/E Ratio | ★ $31.41 | $34.64 |
| Revenue Growth | N/A | ★ 3.62 |
| 52 Week Low | $4.76 | $49.67 |
| 52 Week High | $6.97 | $111.86 |
| Indicator | ICL | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 48.37 |
| Support Level | $5.13 | $100.51 |
| Resistance Level | $5.53 | $101.43 |
| Average True Range (ATR) | 0.11 | 0.44 |
| MACD | -0.06 | 0.10 |
| Stochastic Oscillator | 0.00 | 49.80 |
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and growing solutions. These segments all contribute to the company's development of agriculture, food, and engineered material products and services. Maximum revenue is generated from its phosphate solutions segment which uses phosphate commodity products, such as phosphate rock and fertilizer-grade phosphoric acid (green phosphoric acid), to produce specialty products. This segment also produces and markets phosphate-based fertilizers. Geographically, the company generates revenue from Brazil, the United States of America, China, United Kingdom, Germany, Spain, Israel, France, India, Netherlands, and other countries.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.